Page last updated: 2024-11-06

arctigenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Arctigenin is a natural lignan found in the roots of Arctium lappa (burdock) and other plants. It has shown promising biological activity in various studies, including anti-cancer, anti-inflammatory, and neuroprotective effects.

Arctigenin has been investigated for its potential to inhibit the growth of cancer cells through multiple mechanisms, such as inducing apoptosis (programmed cell death), blocking cell cycle progression, and inhibiting angiogenesis (formation of new blood vessels). Its anti-inflammatory properties have been attributed to its ability to suppress the production of inflammatory mediators like cytokines and chemokines.

Moreover, research has shown that arctigenin can protect neurons from damage caused by oxidative stress and inflammation, making it a potential therapeutic agent for neurodegenerative disorders like Alzheimer's and Parkinson's disease.

Arctigenin's complex structure makes its synthesis challenging. However, researchers have developed various synthetic routes, including those based on the use of enzymes and biocatalysts, to improve the efficiency and sustainability of its production. Ongoing research focuses on understanding its detailed mechanisms of action, optimizing its delivery and bioavailability, and exploring its potential in clinical applications.'

arctigenin: precursor to catechols; in many plants [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64981
CHEMBL ID435734
CHEBI ID79
SCHEMBL ID381820
MeSH IDM0195132

Synonyms (63)

Synonym
HMS3268E18
2(3h)-furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3r,4r)-
c21h24o6
NCGC00025291-01
tocris-1777
MEGXP0_001799
(3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]tetrahydrofuran-2-one
arctigenen
2(3h)-furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3r-trans)-
7770-78-7
arctigenin
(-)-arctigenin
ACON1_000416
NCGC00025291-02
BRD-K53523901-001-01-0
(3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
(3r,4r)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)dihydrofuran-2(3h)-one
chebi:79 ,
CHEMBL435734
S3897
unii-u76mr9vs6m
u76mr9vs6m ,
bdbm50375656
unii-2fd8l150e7
144901-91-7
arctigenin, (+/-)-
2(3h)-furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, trans-
2(3h)-furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3r,4r)-rel-
arctigenin, trans-((+/-)-
(+/-)-arctigenin
2fd8l150e7 ,
AKOS015897121
arctigenin, trans-(-)-
arctigenin [inci]
arctigenin, (-)-
HY-N0035
SCHEMBL381820
(3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3h)-furanone
AC-33952
Q-100825
2(3h)-furanone, 4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-, (3r,4r)-
HB0119
SR-01000597504-1
sr-01000597504
(-)-arctigenin, >=95% (lc/ms-elsd)
mfcd00870597
NCGC00025291-04
4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-(3r-trans)-2(3h)-furanone
4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-(3r,4r)-2(3h)-furanone
(3r-trans)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy- 3-methoxyphenyl)methyl]-4,5-dihydrofuran-2(3h)-one
Q4787603
HMS3676H04
HMS3412H04
EQC ,
(3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(3-methoxy-4-oxidanyl-phenyl)methyl]oxolan-2-one
STL565840
CCG-268327
DTXSID60998919
AS-56162
(3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]-3- [(4-hydroxy-3-methoxyphenyl)methyl]-2-tetrahydrofuranone
NCGC00025291-03
(3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3h)-furanone;2(3h)-furanone,4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-,(3r,4r);(-)-arctigenin;arctigenin;arctigenin(p)
A865172

Research Excerpts

Overview

Arctigenin is an active ingredient present in the seeds of Arctium lappa L. It has been widely applied as a traditional Chinese herbal medicine for treating inflammation.

ExcerptReferenceRelevance
"Arctigenin (ACT) is a novel anti-inflammatory lignan extracted from Arctium lappa L, a herb commonly used in traditional Chinese herbal medicine. "( Anti-inflammatory activity of arctigenin against PCV2 infection in a mouse model.
Chen, J; Chen, R; Chen, X; He, B; Shao, Z; Wu, L; Yang, W; Zhou, D, 2022
)
2.45
"Arctigenin is an active ingredient present in the seeds of Arctium lappa L."( Arctigenin inhibits abnormal germinal center reactions and attenuates murine lupus by inhibiting IFN-I pathway.
Dong, G; Dong, Z; Jing, L; Liang, Y; Sun, M; Xiong, H; Yang, Y; Zhang, X; Zou, M, 2022
)
2.89
"Arctigenin (Arc) is a phenylpropanoid dibenzylbutyrolactone lignan in Arctium lappa L, which has been widely applied as a traditional Chinese herbal medicine for treating inflammation. "( Preventive effects of arctigenin from Arctium lappa L against LPS-induced neuroinflammation and cognitive impairments in mice.
Dong, X; Li, S; Lou, Z; Wang, D; Wang, G; Wu, Y; Yuan, Q; Zhou, X, 2022
)
2.48
"Arctigenin is a bioactive dibenzylbutyrolactone-type lignan exhibiting various pharmacological activities. "( Anti-glutamatergic Effects of Three Lignan Compounds: Arctigenin, Matairesinol and Trachelogenin - An ex vivo Study on Rat Brain Slices.
Boldizsár, I; Borbély, S; Dobolyi, A; Jócsák, G; Koech, PK; Moldován, K; Varró, P; Világi, I, 2023
)
2.6
"Arctigenin (ARC) is a natural lignan isolated from some plants of the Asteraceae family that shows antioxidant property."( Arctigenin improves neuropathy via ameliorating apoptosis and modulating autophagy in streptozotocin-induced diabetic mice.
Ahmed, AAM; El-Sayed, NM; Medras, ZJH; Mostafa, YM, 2023
)
3.07
"Arctigenin (ATG) is a major component of Fructus Arctii, a traditional herbal remedy that reduced proteinuria in diabetic patients. "( Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes.
Azeloglu, EU; Chen, Y; Das, B; Deng, Y; He, JC; Lee, K; Li, X; Liu, R; Ma, Y; Muwonge, AN; Wang, T; Wei, C; Wong, NJ; Yang, S; Zhang, W; Zhong, Y, 2019
)
3.4
"Arctigenin is a natural lignan that is found in burdock with anti‑viral, ‑oxidative, ‑inflammatory and anti‑tumor activities. "( Anti‑metastatic effects of arctigenin are regulated by MAPK/AP‑1 signaling in 4T‑1 mouse breast cancer cells.
Lee, KS; Lee, MG; Nam, KS, 2020
)
2.3
"Arctigenin (AG) is a bioactive ingredient of Arctium lappa L."( Arctigenin exhibits hepatoprotective activity in Toxoplasma gondii-infected host through HMGB1/TLR4/NF-κB pathway.
Aosai, F; Jin, X; Li, YB; Lu, YN; Ma, J; Piao, HN; Piao, J; Piao, LX; Shen, LX; Shi, SY; Xu, GH; Xu, X; Zhao, XD, 2020
)
2.72
"Arctigenin (ARG) is a natural lignan compound extracted from Arctium lappa and has displayed anticancer function and therapeutic effect in a variety of cancers. "( Arctigenin Inhibits Glioblastoma Proliferation through the AKT/mTOR Pathway and Induces Autophagy.
Fei, X; Hong, W; Jiang, Y; Liu, J; Liu, R, 2020
)
3.44
"Arctigenin is a natural lignin and a main active component of Fructus arctii, the dried fruit of Arctium lappa. "( Simultaneous quantification of arctigenin and its glucuronide conjugate in mouse plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
Awazuhara, T; Fujioka, R; Kishino, S; Nukui, Y; Ohno, K; Sato, M; Suzuki, Y; Terashima, T; Tsuchihara, K; Watanabe, K; Yoshida, A, 2021
)
2.35
"Arctigenin (ARC) is a lignan that is abundant in Asteraceae plants, which show anti-inflammatory and anti-cancer activities. "( Arctigenin represses TGF-β-induced epithelial mesenchymal transition in human lung cancer cells.
Lee, SH; Lou, Z; Xu, Y, 2017
)
3.34
"Arctigenin (ARG) is a functional active component that has important physiological and pharmacological activities. "( Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative.
Cai, E; Han, J; Han, M; Li, W; Song, X; Tu, S; Yang, L; Zhao, Y, 2018
)
2.16
"Arctigenin (ATG) is an active compound that exhibits numerous pharmacological activities, which is isolated from the seeds of greater burdock (Arctium lappa Linnaeus), a plant used in traditional Chinese herbal medicine."( The antitumor function of arctigenin in human retinoblastoma cells is mediated by jagged‑1.
Chen, L; Chen, X; Fang, J; Ke, N; Liu, Q; Pi, L, 2019
)
1.54
"Arctigenin is a biologically active lignan extracted from the seeds of Arctium lappa and shows anticancer activity against a variety of human cancers. "( Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling.
Fu, XY; Huang, K; Li, LA; Meng, YG; Song, L; You, YQ, 2014
)
3.29
"Arctigenin is a herb compound extract from Arctium lappa and is reported to exhibit pharmacological properties, including neuronal protection and antidiabetic, antitumor, and antioxidant properties. "( Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.
Da, Y; Gu, C; Hao, J; Kong, Y; Li, W; Li, Y; Xue, Z; Yao, Z; Zhang, K; Zhang, L; Zhang, Q; Zhang, R; Zhang, Z, 2016
)
3.32
"Arctigenin is a bioactive constituent from dried seeds of Arctium lappa L., which was traditionally used as medicine. "( Arctigenin reduces blood pressure by modulation of nitric oxide synthase and NADPH oxidase expression in spontaneously hypertensive rats.
Chen, H; Liu, Y; Sun, C; Wang, G; Yang, M; Yang, S; zhao, Y, 2015
)
3.3
"Arctigenin (ACT) is a phenylpropanoid dibenzylbutyrolactone lignan extracted from the traditional herb Arctium lappa L. "( The antiviral activity of arctigenin in traditional Chinese medicine on porcine circovirus type 2.
Chen, J; Chen, X; Fu, S; Gong, S; Guo, Y; He, Q; Jin, E; Li, W; Qian, Y; Yan, W; Yang, H; Ye, S, 2016
)
2.18
"Arctigenin is a bioactive lignan isolated from the seeds of Arctium lappa L. "( Arctigenin, a lignan from Arctium lappa L., inhibits metastasis of human breast cancer cells through the downregulation of MMP-2/-9 and heparanase in MDA-MB-231 cells.
Lou, C; Zhao, H; Zhao, Y; Zhu, R; Zhu, Z, 2017
)
3.34
"Arctigenin is a plant lignan extracted from Arctium lappa that has been shown to have estrogenic properties. "( The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression.
Chun, SY; Kim, S; Lee, KS; Maxwell, T; Nam, KS, 2017
)
2.15
"Arctigenin is a lignan abundant in Asteraceae plants and has anti-inflammatory, antiobesity, and anticancer activities. "( β-Catenin Mediates Anti-adipogenic and Anticancer Effects of Arctigenin in Preadipocytes and Breast Cancer Cells.
Imm, JY; Lee, J; Lee, SH, 2017
)
2.14
"Arctigenin is a dibenzylbutyrolactone lignan isolated from Bardanae fructus, Arctium lappa L, Saussureamedusa, Torreya nucifera, and Ipomea cairica. "( Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
Liu, C; Luo, L; Yao, X; Yin, Z; Zhao, Z; Zhu, F, 2011
)
3.25
"Arctigenin is a natural plant lignan previously shown to induce G(2)/M arrest in SW480 human colon cancer cells as well as AGS human gastric cancer cells, suggesting its use as a possible cancer chemopreventive agent. "( Cell and nuclear enlargement of SW480 cells induced by a plant lignan, arctigenin: evaluation of cellular DNA content using fluorescence microscopy and flow cytometry.
Jho, EH; Kang, K; Kim, CY; Kim, M; Lee, HJ; Nho, CW; Yoo, JH, 2011
)
2.05
"Arctigenin is a natural compound that had never been previously demonstrated to have a glucose-lowering effect. "( Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice.
Dai, YL; Feng, Y; Gong, J; Hu, F; Hu, YH; Huang, SL; Leng, Y; Tao, YD; Yu, RT, 2012
)
3.26

Effects

Arctigenin (ARG) has been previously reported to exert high biological activities including anti-inflammatory, antiviral and anticancer. The drug has potent antifatigue activity, but its clinical application has been restricted for its poor water solubility.

ExcerptReferenceRelevance
"Arctigenin (ARG) has potent antifatigue activity, but its clinical application has been restricted for its poor water solubility. "( Arctigenin derivatives improve exercise performance in mice: synthesis and biological evaluation.
Li, X; Shi, W; Tan, J; Wu, X; Xu, L; Zeng, W; Zhu, H, 2023
)
3.8
"Arctigenin has been reported as a signal transducer and activator of transcription 3 (STAT3) inhibitor as an anticancer drug with low toxicity."( Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo.
Chi, CH; Hung, CC; Hung, HY; Kuo, CY; Kuo, PC; Tsai, KC; Wu, IT; Yu, KH; Zeng, JW, 2023
)
2.03
"Arctigenin (ARG) has been proved to inhibit the viability of hepatocellular carcinoma (HCC) via inducing apoptosis. "( Activation of reactive oxygen species-mediated mitogen-activated protein kinases pathway regulates both extrinsic and intrinsic apoptosis induced by arctigenin in Hep G2.
Cao, J; Chen, F; Dai, W; Hong, L; Lu, Z; Zhang, S; Zhang, Y; Zhou, H, 2020
)
2.2
"Arctigenin has antidepressant-like effects by attenuating excessive microglial activation and neuroinflammation through the HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB signalling pathways. "( Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways.
Aosai, F; Cheng, JH; Cui, YX; Jin, X; Li, J; Ma, J; Piao, HN; Piao, HR; Piao, LX; Xu, X; Zeng, XY, 2020
)
3.44
"Arctigenin (ATG) has been shown to possess anti-inflammatory, immunemodulatory, anti-viral, anti-microbial, anti-carcinogenic, vasodilatory and anti-platelet aggregation properties. "( Arctigenin Attenuates Ischemia/Reperfusion Induced Ventricular Arrhythmias by Decreasing Oxidative Stress in Rats.
Cao, YJ; Jiang, YF; Jiang, ZA; Li, YJ; Liu, BY; Song, MC; Sun, JP; Wang, C; Wang, YF; Wang, ZH; Yang, J; Yang, R; Yin, HS, 2018
)
3.37
"Arctigenin has been shown to have anti-tumor effects in various types of cancers. "( Arctigenin induces apoptosis in human hepatoblastoma cells.
Hara, F; Kondo, Y; Naoe, A; Suzuki, T; Tsuchiya, T; Uga, N; Watanabe, S; Yasui, T, 2019
)
3.4
"Arctigenin (Arc) has been shown to act on scopolamine-induced memory deficit mice and to provide a neuroprotective effect on cultured cortical neurons from glutamate-induced neurodegeneration through mechanisms not completely defined. "( Neuroprotective effect of arctigenin via upregulation of P-CREB in mouse primary neurons and human SH-SY5Y neuroblastoma cells.
Hao, H; Hu, Y; Kang, T; Liang, W; Ren, L; Sun, D; Wen, Q; Xia, Y; Yan, Y; Yang, J; Zhang, G; Zhang, N; Zhang, X; Zhao, D, 2013
)
2.13
"Arctigenin has displayed anti-arrhythmia effects, both in vivo and in vitro. "( Arctigenin, a potential anti-arrhythmic agent, inhibits aconitine-induced arrhythmia by regulating multi-ion channels.
Bai, G; Jiang, M; Lou, J; Luo, G; Wu, H; Yin, Y; Zhao, Z, 2013
)
3.28
"Arctigenin (ATG) has been reported to possess anti-inflammatory properties. "( Arctigenin attenuates lipopolysaccharide-induced acute lung injury in rats.
Shan, L; Shi, X; Sun, H; Xi, H; Zhou, D, 2015
)
3.3
"Arctigenin has anti-inflammatory and antioxidative effects on LPS-induced acute lung injury, which are associated with modulation of MAPK, HO-1, and iNOS signaling."( Arctigenin Protects against Lipopolysaccharide-Induced Pulmonary Oxidative Stress and Inflammation in a Mouse Model via Suppression of MAPK, HO-1, and iNOS Signaling.
He, BX; Jiang, ZK; Liu, XB; Zhang, WZ, 2015
)
2.58
"Arctigenin (ARG) has been previously reported to exert high biological activities including anti-inflammatory, antiviral and anticancer. "( Mechanism of Arctigenin-Induced Specific Cytotoxicity against Human Hepatocellular Carcinoma Cell Lines: Hep G2 and SMMC7721.
Cao, J; Cao, S; Hua, L; Lu, Z; Zhang, S; Zhou, H, 2015
)
2.23
"Arctigenin (ARG) has been previously reported to exert diverse biological activities including anti-proliferation, anti-inflammatory, and antiviral, etc. "( Integrated in silico and experimental methods revealed that Arctigenin inhibited angiogenesis and HCT116 cell migration and invasion through regulating the H1F4A and Wnt/β-catenin pathway.
Cai, L; Jiang, Q; Li, J; Song, S; Tong, R; Zang, Z; Zhang, S, 2015
)
2.1
"Arctigenin (ARC) has been shown to have an anti-cancer effect in various cell types and tissues. "( Arctigenin Inhibits Lung Metastasis of Colorectal Cancer by Regulating Cell Viability and Metastatic Phenotypes.
Choi, BM; Han, YH; Hong, SH; Jeong, MY; Kee, JY; Kim, DS; Kim, HJ; Mun, JG; Park, SH; Park, SJ; Um, JY, 2016
)
3.32
"Arctigenin has previously been identified as a potential anti-tumor treatment for advanced pancreatic cancer. "( Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin.
Brecht, K; Chibout, SD; Couttet, P; Krähenbühl, S; Paech, F; Pognan, F; Riebel, V; Uteng, M; Wolf, A, 2017
)
2.12
"Arctigenin has been demonstrated to have an anti-inflammatory function, but the precise mechanisms of its action remain to be fully defined. "( Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264.7 cells through suppressing JAK-STAT signal pathway.
Dai, W; Kou, X; Luo, L; Qi, S; Yin, Z, 2011
)
3.25

Treatment

Arctigenin pretreatment significantly alleviated the liver injury, as evidenced by biochemical and histopathological investigations. The protective effects were comparable with Prednisone acetate and Cyclosporin A. ArCTigenin treatment resulted in a significant and dose-dependent inhibition of cell proliferation.

ExcerptReferenceRelevance
"Arctigenin treatment also suppressed the protein expression levels of inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX‑2) and heme oxygenase 1 (HO‑1), and increased the protein expression levels of phosphorylated‑extracellular signal‑regulated kinase 1/2 (p‑ERK1/2) in AMI rats."( Arctigenin exerts protective effects against myocardial infarction via regulation of iNOS, COX‑2, ERK1/2 and HO‑1 in rats.
Yang, Y; Zhang, Y, 2018
)
2.64
"Arctigenin pretreatment significantly alleviated the liver injury, as evidenced by biochemical and histopathological investigations, whose protective effects were comparable with Prednisone acetate and Cyclosporin A."( Quantitative Proteomic Analysis Reveals That Arctigenin Alleviates Concanavalin A-Induced Hepatitis Through Suppressing Immune System and Regulating Autophagy.
Feng, Q; Li, X; Lyu, J; Xia, W; Yang, J; Yao, J; Zhang, G; Zhao, N; Zhao, T; Zhou, G, 2018
)
1.46
"Arctigenin treatment also resulted in a decreased cellular expression of phosphorylated serine/threonine protein kinase AKT, vascular endothelial growth factor receptor 2, and proliferating cell nuclear antigen and inhibited vascular sprouting from aortic rings."( Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
Feng, D; Gu, Y; Laschke, MW; Menger, MD; Scheuer, C, 2013
)
1.34
"Arctigenin treatment resulted in a significant and dose-dependent inhibition of cell proliferation."( Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling.
Fu, XY; Huang, K; Li, LA; Meng, YG; Song, L; You, YQ, 2014
)
2.57
"Arctigenin treatment significantly alleviates disrupted endothelial cells and tortured internal elastic layer observed in the SAH groups (p < 0.01)."( Arctigenin, a Potent Ingredient of Arctium lappa L., Induces Endothelial Nitric Oxide Synthase and Attenuates Subarachnoid Hemorrhage-Induced Vasospasm through PI3K/Akt Pathway in a Rat Model.
Chang, CM; Chang, CZ; Kwan, AL; Lin, CL; Wu, SC, 2015
)
2.58
"Arctigenin treatment significantly inhibited angiogenesis in the CAM."( Arctigenin, a lignan from Arctium lappa L., inhibits metastasis of human breast cancer cells through the downregulation of MMP-2/-9 and heparanase in MDA-MB-231 cells.
Lou, C; Zhao, H; Zhao, Y; Zhu, R; Zhu, Z, 2017
)
2.62
"Arctigenin treatment clearly arrested tumor cells in the G1 phase of the cell cycle."( Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis.
Feng, S; Li, X; Liu, Y; Lv, X; Ma, J; Xiao, J; Yang, H; Yang, S; Zhang, Y, 2012
)
2.54
"Treatment of arctigenin reduced lipid accumulation in differentiated 3T3-L1 adipocytes in a dose- and time-dependent manner without toxicity."( β-Catenin Mediates Anti-adipogenic and Anticancer Effects of Arctigenin in Preadipocytes and Breast Cancer Cells.
Imm, JY; Lee, J; Lee, SH, 2017
)
1.05
"Treatment with arctigenin provided complete protection against experimental JE. "( Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan.
Basu, A; Ghosh, J; Mishra, MK; Swarup, V, 2008
)
0.94

Toxicity

ExcerptReferenceRelevance
"Radix Wikstroemia indica (RWI), named "Liao Ge Wang" in Chinese, is a kind of toxic Chinese herbal medicine (CHM) commonly used in Miao nationality of South China."( Exploring the Q-marker of "sweat soaking method" processed radix Wikstroemia indica: Based on the "effect-toxicity-chemicals" study.
Chen, YL; Feng, G; Hai, Y; He, X; Li, LL; Li, W; Liu, CX; Wu, ZG; Wu, ZJ; Zhang, SC; Zheng, CQ, 2018
)
0.48
" Although Arctii Fructus extract had no toxicity, arctigenin was toxic at a certain dose."( A systematic review on botany, ethnopharmacology, quality control, phytochemistry, pharmacology and toxicity of Arctium lappa L. fruit.
Chang, Y; Chen, S; Cui, Y; Fang, S; He, J; Jin, X; Li, J; Liu, S; Wang, L, 2023
)
1.16

Pharmacokinetics

As compared to normal rats, Cmax and AUC(0-10h) values of oral arctigenin in diabetic rats increased by 356. The validated LC/MS/MS method was successfully applied for the pharmacokinetic study of arctigein in rats.

ExcerptReferenceRelevance
" The validated LC/MS/MS method was successfully applied for the pharmacokinetic study of arctigenin in rats."( Development of an LC/MS/MS method in order to determine arctigenin in rat plasma: its application to a pharmacokinetic study.
Gu, Y; Liu, C; Lu, R; Si, D; Zhang, T; Zhao, GR; Zou, Q, 2013
)
0.86
" The current study aims to provide information regarding the pharmacokinetic properties of AR via various in vitro and in vivo experiments as well as semi-mechanistic pharmacokinetic modeling."( Elucidation of arctigenin pharmacokinetics after intravenous and oral administrations in rats: integration of in vitro and in vivo findings via semi-mechanistic pharmacokinetic modeling.
Gao, Q; Wo, S; Zhang, Y; Zuo, Z, 2014
)
0.76
" As compared to normal rats, Cmax and AUC(0-10h) values of oral arctigenin in diabetic rats increased by 356."( Comparative pharmacokinetics of arctigenin in normal and type 2 diabetic rats after oral and intravenous administration.
Dai, Y; Dong, S; He, NN; Jiang, CJ; Xia, YF; Zeng, XY, 2015
)
0.94
" However, pharmacokinetic studies demonstrated the extensive glucuronidation and hydrolysis of AR in liver, intestine and plasma, which might hinder its in vivo and clinical efficacy after oral administration."( Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L.
Gao, Q; Yang, M; Zuo, Z, 2018
)
0.7

Compound-Compound Interactions

A method involving polyamide column chromatography in combination with HPLC-PAD andHPLC-ESI/MS was successfully developed. Arctigenin was found to be protective in rats with hypertension macroangiopathy.

ExcerptReferenceRelevance
"Enzymatic hydrolysis pretreatment combined with high-speed counter-current chromatography for the transformation and isolation of arctigenin from Fructus Arctii was successfully developed."( Isolation and purification of arctigenin from Fructus Arctii by enzymatic hydrolysis combined with high-speed counter-current chromatography.
Fan, L; Geng, Y; Liu, F; Wang, M; Wang, X; Xi, X, 2014
)
0.9
"To study the protective effect of Arctigenin in goto-kakizaki (GK) rats combined with hypertension macroangiopathy."( [Protective effect of arctigenin in GK rats combined with hypertension macroangiopathy].
Feng, Q; Sun, BC; Xia, WK, 2015
)
1.01

Bioavailability

ExcerptReferenceRelevance
" In order to explore how the bioavailability of oral arctigenin increased under diabetic condition, the absorption behavior of arctigenin was evaluated by in situ single-pass intestinal perfusion (SPIP)."( Comparative pharmacokinetics of arctigenin in normal and type 2 diabetic rats after oral and intravenous administration.
Dai, Y; Dong, S; He, NN; Jiang, CJ; Xia, YF; Zeng, XY, 2015
)
0.95
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Meanwhile, there was no observable acute toxicity of arctigenic acid treatment at the dosage of 280 mg/kg body weight daily in the acute 14-day toxicity study in mice."( Arctigenic acid, the key substance responsible for the hypoglycemic activity of Fructus Arctii.
Feng, Y; Gu, C; Ju, J; Ruan, K; Wang, H; Wang, K; Xu, Z, 2015
)
0.42
" Results showed that dosing of 15."( The antiviral activity of arctigenin in traditional Chinese medicine on porcine circovirus type 2.
Chen, J; Chen, X; Fu, S; Gong, S; Guo, Y; He, Q; Jin, E; Li, W; Qian, Y; Yan, W; Yang, H; Ye, S, 2016
)
0.73
" Based on these results, ARG and its two amino acid derivatives without protective group (ARG8, ARG10) were selected to evaluate their anti-tumor activity in vivo at a dosage of 40 mg/kg."( The Synthesis and Evaluation of Arctigenin Amino Acid Ester Derivatives.
Cai, EB; Jia, CX; Li, W; Song, XZ; Yang, LM; Zhang, WY; Zhao, Y; Zheng, ML, 2016
)
0.72
" Based on these results, ARG6' and ARG9' were selected at a dosage of 40 mg/kg to evaluate their antitumour activity."( Synthesis and antitumour activity of arctigenin amino acid ester derivatives against H22 hepatocellular carcinoma.
Cai, E; Gao, X; Guo, S; Han, M; Wang, Y; Xia, J; Yang, L; Zhao, Y, 2018
)
0.75
" However, the effective dosage of arctigenin was too high for re-sensitization in MDR cell lines."( Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo.
Chi, CH; Hung, CC; Hung, HY; Kuo, CY; Kuo, PC; Tsai, KC; Wu, IT; Yu, KH; Zeng, JW, 2023
)
1.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
arctigenin and isoarctigenin biosynthesis36

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency2.02520.000811.382244.6684AID686978; AID686979
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.00250.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency15.84890.00636.904339.8107AID883
mitogen-activated protein kinase 1Homo sapiens (human)Potency12.58930.039816.784239.8107AID995
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.71580.00798.23321,122.0200AID2546; AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)IC50 (µMol)0.00100.00020.68139.7000AID325818
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
chemotaxisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
negative regulation of cell population proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cerebellar cortex formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
keratinocyte differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
type B pancreatic cell proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cell motilityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Bergmann glial cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
placenta blood vessel developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
labyrinthine layer developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
neuron differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
protein kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
centrosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
plasma membraneDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (188)

Assay IDTitleYearJournalArticle
AID1549841Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as necrotic cells at 20 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0 to 2.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1657509Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
AID1867227Toxicity against human MIA PaCa-2 cells in nutrient-rich medium (DMEM)2022Bioorganic & medicinal chemistry letters, 06-15, Volume: 66Abietane diterpenes from Abies spectabilis and their anti-pancreatic cancer activity against the MIA PaCa-2 cell line.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1898867Induction of glucose uptake in rat L6 myoblasts at 3 uM measured after 2 hrs by liquid scintillation counter2022European journal of medicinal chemistry, Jan-15, Volume: 228Discovery of seneciobipyrrolidine derivatives for the amelioration of glucose homeostasis disorders through 4E-BP1/Akt/AMPK signaling activation.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1304315Reduction in amyloid beta 40 content (unknown origin) expressed in HEK293 cells expressing APP K595N/M596L Swedish mutant at 0.1 uM after 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synthesis and decreasing Aβ content evaluation of arctigenin-4-yl carbamate derivatives.
AID1657510Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
AID409753Cytotoxicity against human PANC1 cells in nutrient-deprived condition2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Novel anticancer agents, kayeassamins C-I from the flower of Kayea assamica of Myanmar.
AID1758637Anti-austerity activity against human MIA PaCa-2 cells assessed as cell killing in nutrient deprived medium2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40A new anti-austerity agent, 4'-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibition of Akt/mTOR pathway.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID293735Selectivity index, ratio of CC50 for MRC5 cells to IC50 for HCMV2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antiviral activity of berberine and related compounds against human cytomegalovirus.
AID1664594Cytotoxicity against human PANC1 cells in nutrient-deprived medium2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
Chemical constituents of Callistemon citrinus from Egypt and their antiausterity activity against PANC-1 human pancreatic cancer cell line.
AID1489043Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Syntheses of cytotoxic novel arctigenin derivatives bearing halogen and alkyl groups on aromatic rings.
AID403995Antiviral activity against HIV assessed as reduction of viral protein production at 0.27 uM1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1687015Anti-austerity activity against nutrient-deprived human PANC-1 cells assessed as cell death incubated for 24 hrs by WST-8 assay
AID1651695Anti-austeritic activity against human PANC1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID725948Toxicity in human Capan1 cells injected BALB/cAJcl-nu-nu mouse assessed as behavior at 50 ug for 6 days in a week upto 28th days treatment started on 15th day tumor injection2013European journal of medicinal chemistry, Feb, Volume: 60Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.
AID1378835Antiausteritic activity against human PANC1 cells in nutrient-deprived medium assessed as decrease in cell viability measured after 24 hrs by WST-8 assay
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1549831Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as early apoptotic cells at 5 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0.22 to 14.25%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1421396Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as survival rate at 100 mg/kg, po qd administered via gavage for several consecutive days measured on day 20 relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID696881Cytotoxicity against human PANC1 cells grown in nutrient-deprived medium after 24 hrs by WST8 assay2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Uvaridacols E-H, highly oxygenated antiausterity agents from Uvaria dac.
AID1464848Antiausteritic activity against human PANC1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Discovery of potential antiausterity agents from the Japanese cypress Chamaecyparis obtusa.
AID1421383Antiparasitic activity against Toxoplasma gondii RH tachyzoites infected in human HeLa cells assessed as decrease in cell shrinkage at 100 uM after 24 hrs by inverted optical microscopic analysis2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID676697Cytotoxicity against human KLM1 cells grown in nutrient-deprived medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1693984Anti-austerity activity against nutrient-deprived human PANC-1 cells assessed as cell death incubated for 24 hrs by WST-8 assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Ancistrobrevidines A-C and related naphthylisoquinoline alkaloids with cytotoxic activities against HeLa and pancreatic cancer cells, from the liana Ancistrocladus abbreviatus.
AID1438024Antiausteritic activity against human PANC1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1303323Toxicity in BALB/cAJcl-nu/nu mouse xenografted with human MIAPaCa2 cells assessed as body weight loss at 7.5 mg/kg, ip measured every fifth day2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1058589Cytotoxicity against human PANC1 cells assessed as cell viability after 24 hrs by WST8 assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Heptaoxygenated xanthones as anti-austerity agents from Securidaca longepedunculata.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1421381Selectivity index, ratio of IC50 for human HeLa cells to ratio of IC50 for Toxoplasma gondii RH tachyzoites2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1303321Antitumor activity against human MIAPaCa2 cells xenografted in BALB/cAJcl-nu/nu mouse assessed as reduction in tumor volume at 7.5 mg/kg, ip measured every fourth day relative to control2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer.
AID1464851Antiausteritic activity against human PSN1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Discovery of potential antiausterity agents from the Japanese cypress Chamaecyparis obtusa.
AID1667024Anti-austerity activity against human PANC1 cells assessed as cell killing incubated in nutrient deprived medium2020Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7
Synthesis of guggulsterone derivatives as potential anti-austerity agents against PANC-1 human pancreatic cancer cells.
AID1303319Antitumor activity against human MIAPaCa2 cells xenografted in BALB/cAJcl-nu/nu mouse assessed as tumor volume at 7.5 mg/kg, ip measured every fourth day (Rvb = 1917.6 +/- 280.3 mm3)2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer.
AID1662706Cytotoxicity against Spodoptera frugiperda Sf9 cells assessed as reduction in cell viability2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Discovery of stereospecific cytotoxicity of (8R,8'R)-trans-arctigenin against insect cells and structure-activity relationship on aromatic ring.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1549827Growth inhibition of human PANC1 cells in nutrient-deprived medium incubated for 24 hrs by MTT assay2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1421386Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as inhibition of number of intraperitoneal tachyzoite in abdominal cavity at 200 mg/kg, po qd administered via gavage for 4 consecutive days measured on day 5 by light 2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1064247Cytotoxicity against human PANC1 cells in nutrient-deprived medium after 24 hrs by WST-8 assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Discovery of 2-pyridineformamide thiosemicarbazones as potent antiausterity agents.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1304317Reduction in amyloid beta 40 content (unknown origin) expressed in HEK293 cells expressing APP K595N/M596L Swedish mutant at 10 uM after 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synthesis and decreasing Aβ content evaluation of arctigenin-4-yl carbamate derivatives.
AID430989Cytotoxicity against human PANC1 cells in nutrient-deprived condition assessed as 50% cell death after 24 hrs by WST8 assay2009Journal of natural products, Jul, Volume: 72, Issue:7
Chemical constituents of propolis from Myanmar and their preferential cytotoxicity against a human pancreatic cancer cell line.
AID676700Cytotoxicity against human MIAPaCa2 cells grown in nutrient-rich medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1385469Antiausteritic activity against human MIAPaCa2 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
AID1385468Antiausteritic activity against human PANC1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
AID1549836Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as late apoptotic cells at 10 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0 to 0.9%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1662704Cytotoxicity against Aedes albopictus NIAS-AeAl-2 cells assessed as reduction in cell viability2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Discovery of stereospecific cytotoxicity of (8R,8'R)-trans-arctigenin against insect cells and structure-activity relationship on aromatic ring.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1421380Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID725950Cytotoxicity against human PANC1 cells assessed as cell viability after 3 hrs by WST-8 cells2013European journal of medicinal chemistry, Feb, Volume: 60Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.
AID311568Cytotoxicity against human PANC1 cells assessed as cell viability2007Journal of natural products, Oct, Volume: 70, Issue:10
Bioactive secondary metabolites from Boesenbergia pandurata of Myanmar and their preferential cytotoxicity against human pancreatic cancer PANC-1 cell line in nutrient-deprived medium.
AID1662703Induction of DNA degradation in Spodoptera frugiperda Sf9 cells by DNA ladder assay2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Discovery of stereospecific cytotoxicity of (8R,8'R)-trans-arctigenin against insect cells and structure-activity relationship on aromatic ring.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID403996Antiviral activity against HIV assessed as reduction of viral protein production at 0.52 uM1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1867226Preferential cytotoxicity against human MIA PaCa-2 cells in nutrient-deprived medium2022Bioorganic & medicinal chemistry letters, 06-15, Volume: 66Abietane diterpenes from Abies spectabilis and their anti-pancreatic cancer activity against the MIA PaCa-2 cell line.
AID313354Cytotoxicity against human PANC1 cells in nutrient deprived medium after 24 hrs2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1226642Increase in glucose uptake in rat L6 cells at 0.75 uM to 3 uM pre-treated with compound for 30 mins using 2-deoxy-D-[1,2-3H]glucose and measured after 2 hrs by liquid scintillation counting method2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Design and synthesis of novel arctigenin analogues for the amelioration of metabolic disorders.
AID1549835Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as early apoptotic cells at 10 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0.22 to 14.25%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1617250Anti-austerity activity against nutrient-deprived human PANC1 cells assessed as cell death incubated for 24 hrs by WST-8 assay
AID366346Cytotoxicity against human PANC1 cells under nutrient-deprived medium after 24 hrs by serial dilution method2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Novel anticancer agents, kayeassamins A and B from the flower of Kayea assamica of Myanmar.
AID1303316Cytotoxicity against human PANC1 cells at 30 uM cultured in dulbecco's modified eagle's medium2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer.
AID676701Cytotoxicity against human KLM1 cells grown in nutrient-rich medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1421392Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as decrease in GSH level in liver at 100 mg/kg, po qd administered via gavage for 4 consecutive days measured on day 52018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1464850Antiausteritic activity against human Capan1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Discovery of potential antiausterity agents from the Japanese cypress Chamaecyparis obtusa.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID725949Toxicity in human Capan1 cells injected BALB/cAJcl-nu-nu mouse assessed as body weight at 50 ug for 6 days in a week upto 28th days treatment started on 15th day tumor injection2013European journal of medicinal chemistry, Feb, Volume: 60Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.
AID1549833Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as necrotic cells at 5 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0 to 2.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1177069Cytotoxicity against human A549 cells after 4 days under glucose-starved conditions by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis and cytotoxicity evaluation of 4-amino-4-dehydroxylarctigenin derivatives in glucose-starved A549 tumor cells.
AID1464852Antiausteritic activity against human KLM1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Discovery of potential antiausterity agents from the Japanese cypress Chamaecyparis obtusa.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1177070Cytotoxicity against human A549 cells after 4 days under normal conditions by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis and cytotoxicity evaluation of 4-amino-4-dehydroxylarctigenin derivatives in glucose-starved A549 tumor cells.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1549825Growth inhibition of human PANC1 cells in nutrient-deprived medium at 10 uM incubated for 24 hrs by MTT assay (Rvb = 0.0 +/- 1.9%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1617255Cytotoxicity against nutrient-rich DMEM cultured human PANC1 cells at PC50 incubated for 24 hrs by WST-8 assay
AID1304314Reduction in amyloid beta 40 content (unknown origin) expressed in HEK293 cells expressing APP K595N/M596L Swedish mutant at 20 uM after 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synthesis and decreasing Aβ content evaluation of arctigenin-4-yl carbamate derivatives.
AID725951Antitumor activity against human Capan1 cells injected into BALB/cAJcl-nu-nu mouse assessed as reduction in tumor weight at 50 ug for 6 days in a week upto 28th days treatment started on 15th day tumor injection2013European journal of medicinal chemistry, Feb, Volume: 60Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1662702Effect on 28s ribosomal RNA expression in Spodoptera frugiperda Sf9 cells2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Discovery of stereospecific cytotoxicity of (8R,8'R)-trans-arctigenin against insect cells and structure-activity relationship on aromatic ring.
AID1304316Reduction in amyloid beta 40 content (unknown origin) expressed in HEK293 cells expressing APP K595N/M596L Swedish mutant at 1 uM after 24 hrs by ELISA2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synthesis and decreasing Aβ content evaluation of arctigenin-4-yl carbamate derivatives.
AID1549839Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as early apoptotic cells at 20 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0.22 to 14.25%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1617106Cytotoxicity against nutrient deprived human PANC1 cells assessed as induction of cell killing incubated for 24 hrs by WST-8 assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana
AID1549830Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as live cells at 5 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 85.75 to 96.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1549840Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as late apoptotic cells at 20 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0 to 0.9%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1549834Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as live cells at 10 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 85.75 to 96.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1421384Antiparasitic activity against Toxoplasma gondii RH tachyzoites infected in human HeLa cells assessed as decrease in number of cell death at 100 uM after 24 hrs by inverted optical microscopic analysis2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID676694Cytotoxicity against human PANC1 cells grown in nutrient-deprived medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1898840Induction of glucose uptake in rat L6 myoblasts assessed as 2-DG concentration at 25 uM preincubated for 3 hrs and in presence of 2-deoxyglucose measured after 1 hrs by DNTB reagent based colorimetric assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Discovery of seneciobipyrrolidine derivatives for the amelioration of glucose homeostasis disorders through 4E-BP1/Akt/AMPK signaling activation.
AID1696140Anticancer activity against human PANC-1 cells assessed as reduction in cell viability in nutrient-deprived medium after 24 hrs by WST-8 assay
AID1226643Increase in glucose uptake in rat L6 cells at 3 umol/L pre-treated with compound for 30 mins using 2-deoxy-D-[1,2-3H]glucose and measured after 2 hrs by liquid scintillation counting method relative to control2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Design and synthesis of novel arctigenin analogues for the amelioration of metabolic disorders.
AID404005Inhibition of HIV reverse transcriptase at 0.27 uM1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1489042Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Syntheses of cytotoxic novel arctigenin derivatives bearing halogen and alkyl groups on aromatic rings.
AID1549826Growth inhibition of human PANC1 cells in nutrient-rich medium at 10 uM incubated for 24 hrs by MTT assay (Rvb = 0.0 +/- 3.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID430984Cytotoxicity against human PANC1 cells in nutrient-deprived condition assessed as 100% cell death after 24 hrs by WST8 assay2009Journal of natural products, Jul, Volume: 72, Issue:7
Chemical constituents of propolis from Myanmar and their preferential cytotoxicity against a human pancreatic cancer cell line.
AID404006Inhibition of HIV reverse transcriptase at 0.52 uM1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID676698Cytotoxicity against human PANC1 cells grown in nutrient-rich medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1549832Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as late apoptotic cells at 5 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0 to 0.9%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1385470Antiausteritic activity against human PSN1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
AID1549837Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as necrotic cells at 10 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 0 to 2.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID1765181Anti-austerity activity against human PANC-1 cells assessed as cell killing incubated for 24 hrs in nutrient deprived medium by CCK8 assay
AID676699Cytotoxicity against human PSN1 cells grown in nutrient-rich medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1303315Cytotoxicity against human PANC1 cells cultured in nutrient-deprived medium2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer.
AID91560Inhibitory activity against strand transfer by HIV-1 Integrase at 100 uM1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase.
AID1503761Antiausteritic activity against human PANC1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2017Journal of natural products, 10-27, Volume: 80, Issue:10
Jozilebomines A and B, Naphthylisoquinoline Dimers from the Congolese Liana Ancistrocladus ileboensis, with Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Cell Line.
AID1421398Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as increase in survival rate by measuring mortality day at 100 mg/kg, po qd administered via gavage for several consecutive days measured on day 10 (Rvb = 9 to 11 days)2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID293734Antiviral activity against HCMV in MRC5 cells by plaque reduction assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antiviral activity of berberine and related compounds against human cytomegalovirus.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1328102Antiausteritic activity against human PANC1 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2016Journal of natural products, 08-26, Volume: 79, Issue:8
Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
AID676696Cytotoxicity against human MIAPaCa2 cells grown in nutrient-deprived medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1758638Anti-austerity activity against human PSN1 cells assessed as cell killing in nutrient deprived medium2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40A new anti-austerity agent, 4'-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibition of Akt/mTOR pathway.
AID1421393Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as increase in body weight at 100 mg/kg, po qd administered via gavage for several consecutive days2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1617112Cytotoxicity against DMEM cultured human PANC1 cells assessed as reduction in cell viability at PC50 incubated for 24 hrs by WST-8 assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana
AID1657511Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1421379Antiparasitic activity against Toxoplasma gondii RH tachyzoites by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325818Inhibition of MKK12007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1549838Induction of apoptosis in human PANC1 cells in nutrient-deprived medium assessed as live cells at 20 uM incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 85.75 to 96.8%)2019European journal of medicinal chemistry, May-15, Volume: 170Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.
AID436320Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Phenylpropanoids from Daphne feddei and their inhibitory activities against NO production.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1421389Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as reduction in serum ALT level at 100 mg/kg, po qd administered via gavage for 4 consecutive days measured on day 52018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1421399Antiparasitic activity against Toxoplasma gondii RH tachyzoites infected in human HeLa cells assessed as increase in cell survival at 100 uM after 24 hrs by trypan blue assay relative to spiramycin2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1662705Cytotoxicity against human HL60 cells assessed as reduction in cell viability2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Discovery of stereospecific cytotoxicity of (8R,8'R)-trans-arctigenin against insect cells and structure-activity relationship on aromatic ring.
AID91438Inhibitory activity against 3'-processing by HIV-1 Integrase at 100 uM1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase.
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID676695Cytotoxicity against human PSN1 cells grown in nutrient-deprived medium after 24 hrs by WST8 assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID293733Cytotoxicity against MRC5 cells2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antiviral activity of berberine and related compounds against human cytomegalovirus.
AID1758636Anti-austerity activity against human PANC-1 cells assessed as cell killing in nutrient deprived medium2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40A new anti-austerity agent, 4'-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibition of Akt/mTOR pathway.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1464849Antiausteritic activity against human MIAPaCa2 cells in nutrient-deprived medium measured after 24 hrs by WST8 assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Discovery of potential antiausterity agents from the Japanese cypress Chamaecyparis obtusa.
AID1421390Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as reduction in serum AST level at 100 mg/kg, po qd administered via gavage for 4 consecutive days measured on day 52018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID403998Therapeutic index, ratio of inhibition of human H9 cells to EC50 for HIV11998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1421385Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as inhibition of number of intraperitoneal tachyzoite in abdominal cavity at 100 mg/kg, po qd administered via gavage for 4 consecutive days measured on day 5 by light 2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1421387Antiparasitic activity against Toxoplasma gondii RH infected in Kunming mouse assessed as improvement of hepatomegaly at 100 mg/kg, po qd administered via gavage for 4 consecutive days measured on day 52018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
AID325819Inhibition of LPS induced iNOS induced expression in mouse Raw264.7cells2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID403997Antiviral activity against HIV1 infected in human H9 cells assessed inhibition of viral replication1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1758639Anti-austerity activity against human KLM-1 cells assessed as cell killing in nutrient deprived medium2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40A new anti-austerity agent, 4'-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibition of Akt/mTOR pathway.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (278)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (2.52)18.2507
2000's29 (10.43)29.6817
2010's168 (60.43)24.3611
2020's74 (26.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.16 (24.57)
Research Supply Index5.65 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.35%)5.53%
Reviews10 (3.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other272 (96.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]